Genetic testing company GRAIL has partnered with non-profits Whitman-Walker Institute and Cancer Support Community (CSC) on a study aimed at advancing health equity in cancer screening and care using GRAIL's multi-cancer early detection (MCED) test.
The collaboration aims to increase early cancer screening in underrepresented populations, assess the feasibility of using GRAIL’s test in diverse patient populations, and increase access to MCED testing in diverse communities. In addition, participants who receive a positive result from the Galleri test will be offered support and navigation services from diagnosis through treatment by CSC.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.